Thursday, April 17, 2008

Not my headline.

Forbes: Pfizer flops.

1 comment:

Anonymous said...

Even with the current decrease in share price it is still over-valued, as are most pharmaceutical issues. I am amazed by the ability of the Pharma houses to "strongarm" the analysts into valuing what is "unseen over the horizon" as opposed to current and near-term performance.